Sintx Technologies, Inc. (NASDAQ:SINT) Short Interest Up 20.3% in December

Sintx Technologies, Inc. (NASDAQ:SINT) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 206,724 shares, a growth of 20.3% from the December 15th total of 171,790 shares. Currently, 5.8% of the company’s shares are short sold. Based on an average daily volume of 40,662 shares, the days-to-cover ratio is presently 5.1 days. Based on an average daily volume of 40,662 shares, the days-to-cover ratio is presently 5.1 days. Currently, 5.8% of the company’s shares are short sold.

Sintx Technologies Trading Down 1.3%

Shares of NASDAQ:SINT traded down $0.05 during mid-day trading on Tuesday, hitting $3.69. 21,847 shares of the company traded hands, compared to its average volume of 35,898. The stock has a 50-day moving average price of $3.67 and a two-hundred day moving average price of $3.64. Sintx Technologies has a 12-month low of $1.71 and a 12-month high of $7.36. The stock has a market cap of $13.58 million, a P/E ratio of -0.65 and a beta of 0.65.

Sintx Technologies (NASDAQ:SINT) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($3.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.91). The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.20 million. Sintx Technologies had a negative net margin of 775.12% and a negative return on equity of 218.25%.

Insider Activity at Sintx Technologies

In other Sintx Technologies news, CIO Gregg R. Honigblum bought 8,200 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was acquired at an average price of $4.26 per share, with a total value of $34,932.00. Following the completion of the purchase, the executive directly owned 201,067 shares of the company’s stock, valued at approximately $856,545.42. This trade represents a 4.25% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders bought 83,200 shares of company stock worth $322,282. 4.08% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in Sintx Technologies by 33.5% in the 2nd quarter. Geode Capital Management LLC now owns 15,339 shares of the company’s stock worth $49,000 after purchasing an additional 3,848 shares in the last quarter. Veracity Capital LLC boosted its stake in shares of Sintx Technologies by 10.3% in the 3rd quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after buying an additional 7,464 shares during the last quarter. Finally, Virtus Wealth Solutions LLC bought a new position in shares of Sintx Technologies in the third quarter valued at approximately $388,000. 18.38% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wall Street Zen cut Sintx Technologies from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Sintx Technologies in a report on Wednesday, October 8th. Finally, Ascendiant Capital Markets decreased their price target on shares of Sintx Technologies from $25.00 to $16.00 and set a “buy” rating for the company in a research note on Monday, December 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.00.

Sintx Technologies Company Profile

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.